Loading…
Employees: 3,514
Size Lushang Freda Pharmaceutical (600223.SS) is a China Real Estate company (Real Estate Development) with a market value of $813M, the 2719th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥5.33 on 6 Nov 2026.
Performance Over six months the shares fell 18.6%, against -10.2% for the median peer and -16.4% for the China market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue grew 1.9% over the last twelve months (peer median -1.8%); the operating margin is 3.9% (peer median 14.2%).
Valuation It trades at 29.4× forward earnings against a peer median of 8.8× (2nd most expensive of 8).
Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.83B | CN¥3.63B | CN¥3.96B | CN¥4.55B | CN¥12.9B |
| Revenue growth | — | -8% | -13% | -65% | — |
| Gross profit | CN¥2.20B | CN¥1.85B | CN¥2.02B | CN¥2.05B | CN¥3.04B |
| EBITDA | n/a | CN¥295M | CN¥325M | CN¥383M | CN¥658M |
| Net income | CN¥157M | CN¥188M | CN¥244M | CN¥303M | CN¥45.5M |
| Free cash flow | CN¥225M | CN¥228M | CN¥227M | CN¥325M | CN¥963M |
| Capital expenditure | CN¥99.2M | CN¥110M | CN¥157M | CN¥211M | CN¥166M |
| Total debt | CN¥88.9M | CN¥149M | CN¥300M | CN¥2.18B | CN¥9.45B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600223.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.3% | -4.4% | 9th lowest of 21 |
| 6-month return | -18.6% | -10.2% | 6th lowest of 20 |
| Distance from 52-week high | -36.3% | -21.3% | 7th lowest of 21 |
| Revenue growth (TTM) | +1.9% | -1.8% | 8th highest of 21 |
| Operating margin | 3.9% | 14.2% | 9th lowest of 21 |
| Forward P/E | 29.4× | 8.8× | 2nd most expensive of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Lushang Freda Pharmaceutical 600223.SS | China | $813M | -19% | +2% | 4% | 29.4× | n/a | n/a |
| FastPartner FPAR-A.ST | Sweden | $810M | -7% | -2% | 66% | 11.5× | n/a | n/a |
| Logan 3380.HK | Hong Kong | $816M | -9% | -69% | -178% | n/a | n/a | n/a |
| Sun Frontier Fudousan 8934.T | Japan | $816M | -16% | +3% | 22% | 6.9× | n/a | n/a |
| Shenzhen New Nanshan Holding (Group) 002314.SZ | China | $833M | -19% | -55% | -36% | n/a | n/a | n/a |
| Jm AB JM.ST | Sweden | $834M | +7% | -14% | 1% | 34.4× | n/a | n/a |
| Jointown Aesthetics ValleyCo.,Ltd 000615.SZ | China | $791M | -11% | -35% | -131% | n/a | n/a | n/a |
| Metro Land 600683.SS | China | $839M | -48% | +1,029% | -10% | n/a | n/a | n/a |
| Sky Harbour SKYH | United States | $839M | +4% | +62% | -81% | n/a | n/a | n/a |
| Shenzhen Tellus 000025.SZ | China | $843M | -16% | -60% | 21% | n/a | n/a | n/a |
| Morguard MRC.TO | Canada | $844M | -6% | -1% | 49% | 5.1× | n/a | n/a |
| Wing Tai W05.SI | Singapore | $846M | -10% | +168% | 6% | n/a | n/a | n/a |
| Guanghui Logistics 600603.SS | China | $780M | -23% | -24% | 13% | n/a | n/a | n/a |
| Robyg ROB.WA | Poland | $779M | n/a | +63% | 15% | n/a | n/a | n/a |
| Bright Real Estate 600708.SS | China | $849M | -33% | -54% | -82% | n/a | n/a | n/a |
| Dios Fastigheter DIOS.ST | Sweden | $851M | -9% | +1% | 66% | 8.8× | n/a | n/a |
| Platzer Fastigheter PLAZ-B.ST | Sweden | $776M | -12% | +1% | 74% | 9.2× | n/a | n/a |
| Country Garden 2007.HK | Hong Kong | $853M | -49% | -42% | -51% | n/a | n/a | n/a |
| Archicom ARH.WA | Poland | $773M | -2% | +70% | 16% | 7.4× | n/a | n/a |
| Miramar Hotel & Investment 0071.HK | Hong Kong | $862M | -10% | -11% | 22% | n/a | n/a | n/a |
| United Overseas Australia UOS.AX | Australia | $765M | -10% | +13% | 37% | n/a | n/a | n/a |